Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.47
WAG's Cash to Debt is ranked higher than
65% of the 510 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.59 vs. WAG: 0.47 )
WAG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.47

Equity to Asset 0.57
WAG's Equity to Asset is ranked higher than
86% of the 516 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. WAG: 0.57 )
WAG' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.64
Current: 0.57

0.52
0.64
F-Score: 6
Z-Score: 5.67
M-Score: -2.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.65
WAG's Operating margin (%) is ranked higher than
88% of the 518 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.55 vs. WAG: 5.65 )
WAG' s 10-Year Operating margin (%) Range
Min: 4.84   Max: 6.05
Current: 5.65

4.84
6.05
Net-margin (%) 3.76
WAG's Net-margin (%) is ranked higher than
87% of the 518 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.14 vs. WAG: 3.76 )
WAG' s 10-Year Net-margin (%) Range
Min: 2.97   Max: 3.8
Current: 3.76

2.97
3.8
ROE (%) 13.20
WAG's ROE (%) is ranked higher than
85% of the 509 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.62 vs. WAG: 13.20 )
WAG' s 10-Year ROE (%) Range
Min: 11.66   Max: 18.39
Current: 13.2

11.66
18.39
ROA (%) 7.56
WAG's ROA (%) is ranked higher than
91% of the 518 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.03 vs. WAG: 7.56 )
WAG' s 10-Year ROA (%) Range
Min: 6.36   Max: 10.94
Current: 7.56

6.36
10.94
ROC (Joel Greenblatt) (%) 29.83
WAG's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.47 vs. WAG: 29.83 )
WAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 22.73   Max: 30.69
Current: 29.83

22.73
30.69
Revenue Growth (%) 3.50
WAG's Revenue Growth (%) is ranked higher than
72% of the 461 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. WAG: 3.50 )
WAG' s 10-Year Revenue Growth (%) Range
Min: 3.5   Max: 16.5
Current: 3.5

3.5
16.5
EBITDA Growth (%) 6.40
WAG's EBITDA Growth (%) is ranked higher than
79% of the 417 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.00 vs. WAG: 6.40 )
WAG' s 10-Year EBITDA Growth (%) Range
Min: 6.1   Max: 17.9
Current: 6.4

6.1
17.9
EPS Growth (%) 6.50
WAG's EPS Growth (%) is ranked higher than
77% of the 392 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.10 vs. WAG: 6.50 )
WAG' s 10-Year EPS Growth (%) Range
Min: 1.5   Max: 20
Current: 6.5

1.5
20
» WAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

WAG Guru Trades in Q3 2013

Paul Tudor Jones 100,000 sh (New)
Jim Simons 1,451,800 sh (New)
Louis Moore Bacon 10,000 sh (New)
George Soros 500,000 sh (New)
John Hussman 296,500 sh (+46.42%)
Jeremy Grantham 3,640,147 sh (+28.17%)
Ken Fisher 5,755 sh (+18.44%)
Steven Cohen 73,290 sh (+15%)
Manning & Napier Advisors, Inc 97,616 sh (+5.34%)
Tom Gayner 2,149,200 sh (+0.07%)
Caxton Associates 800,000 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Vanguard Health Care Fund 12,465,900 sh (unchged)
Joel Greenblatt Sold Out
John Buckingham 152,337 sh (-0.35%)
First Pacific Advisors 2,288,500 sh (-0.38%)
Pioneer Investments 2,324,514 sh (-1.22%)
Bill Frels 16,788 sh (-1.32%)
Larry Robbins 7,442,926 sh (-1.75%)
RS Investment Management 49,300 sh (-2.18%)
Dodge & Cox 6,069 sh (-6.18%)
Mario Gabelli 191,450 sh (-7.85%)
James Barrow 7,571,176 sh (-12.45%)
John Rogers 104,630 sh (-36.38%)
Chuck Royce 3,000 sh (-94.2%)
» More
Q4 2013

WAG Guru Trades in Q4 2013

John Keeley 3,682 sh (New)
Andreas Halvorsen 11,604,944 sh (New)
Steven Cohen 335,584 sh (+357.89%)
RS Investment Management 52,100 sh (+5.68%)
George Soros 515,700 sh (+3.14%)
First Pacific Advisors 2,295,200 sh (+0.29%)
Pioneer Investments 2,325,918 sh (+0.06%)
Steven Romick 2,175,000 sh (unchged)
Dodge & Cox 6,069 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
John Rogers Sold Out
Tom Gayner 2,147,450 sh (-0.08%)
Ken Fisher 5,737 sh (-0.31%)
John Buckingham 150,884 sh (-0.95%)
Mario Gabelli 188,750 sh (-1.41%)
Jeremy Grantham 3,555,906 sh (-2.31%)
Jim Simons 1,387,600 sh (-4.42%)
James Barrow 6,972,657 sh (-7.91%)
Vanguard Health Care Fund 10,913,200 sh (-12.46%)
Bill Frels 14,013 sh (-16.53%)
Larry Robbins 5,951,526 sh (-20.04%)
Manning & Napier Advisors, Inc 70,004 sh (-28.29%)
John Hussman 150,000 sh (-49.41%)
Paul Tudor Jones 14,008 sh (-85.99%)
» More
Q1 2014

WAG Guru Trades in Q1 2014

Louis Moore Bacon 244,750 sh (New)
John Griffin 3,435,000 sh (New)
Stanley Druckenmiller 1,240,000 sh (New)
Andreas Halvorsen 24,105,841 sh (+107.72%)
George Soros 850,000 sh (+64.82%)
Paul Tudor Jones 19,946 sh (+42.39%)
RS Investment Management 56,200 sh (+7.87%)
First Pacific Advisors 2,304,500 sh (+0.41%)
Larry Robbins 500,000 sh (unchged)
John Keeley 3,682 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
Dodge & Cox 6,069 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
John Hussman Sold Out
John Buckingham Sold Out
Jim Simons Sold Out
Pioneer Investments 2,316,700 sh (-0.4%)
Tom Gayner 2,135,000 sh (-0.58%)
Manning & Napier Advisors, Inc 69,126 sh (-1.25%)
Vanguard Health Care Fund 10,073,000 sh (-7.7%)
Mario Gabelli 172,950 sh (-8.37%)
Bill Frels 12,663 sh (-9.63%)
Larry Robbins 5,190,926 sh (-12.78%)
Ken Fisher 4,263 sh (-25.69%)
Jeremy Grantham 662,105 sh (-81.38%)
James Barrow 960,997 sh (-86.22%)
Steven Cohen 24,535 sh (-92.69%)
» More
Q2 2014

WAG Guru Trades in Q2 2014

Lee Ainslie 1,318,963 sh (New)
Caxton Associates 70,000 sh (New)
Jean-Marie Eveillard 1,306,571 sh (New)
Daniel Loeb 700,000 sh (New)
John Griffin 6,245,000 sh (+81.8%)
George Soros 1,300,000 sh (+52.94%)
RS Investment Management 66,100 sh (+17.62%)
Ken Fisher 4,754 sh (+11.52%)
First Pacific Advisors 2,314,100 sh (+0.42%)
John Keeley 3,683 sh (+0.03%)
Eric Mindich 1,000,000 sh (unchged)
Steven Cohen 150,000 sh (unchged)
Bill Frels 12,663 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Larry Robbins 500,000 sh (unchged)
Stanley Druckenmiller 1,240,000 sh (unchged)
Pioneer Investments 2,314,940 sh (-0.08%)
Mario Gabelli 171,700 sh (-0.72%)
Dodge & Cox 5,669 sh (-6.59%)
James Barrow 819,847 sh (-14.69%)
Andreas Halvorsen 20,137,154 sh (-16.46%)
Vanguard Health Care Fund 7,128,300 sh (-29.23%)
Larry Robbins 3,577,926 sh (-31.07%)
Paul Tudor Jones 12,930 sh (-35.17%)
Louis Moore Bacon 54,320 sh (-77.81%)
Manning & Napier Advisors, Inc 14,515 sh (-79%)
Jeremy Grantham 76,100 sh (-88.51%)
» More
» Details

Insider Trades

Latest Guru Trades with WAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Griffin 2014-06-30 Add 81.8%2.07%$63.4 - $76.08 $ 63.67-9%6245000
Lee Ainslie 2014-06-30 New Buy1.4%$63.4 - $76.08 $ 63.67-9%1318963
Daniel Loeb 2014-06-30 New Buy0.64%$63.4 - $76.08 $ 63.67-9%700000
Vanguard Health Care Fund 2014-06-30 Reduce -29.23%0.56%$63.4 - $76.08 $ 63.67-9%7128300
George Soros 2014-06-30 Add 52.94%0.25%$63.4 - $76.08 $ 63.67-9%1300000
Jean-Marie Eveillard 2014-06-30 New Buy0.23%$63.4 - $76.08 $ 63.67-9%1306571
John Griffin 2014-03-31 New Buy2.5%$55.57 - $69.09 $ 63.672%3435000
John Hussman 2014-03-31 Sold Out 0.61%$55.57 - $69.09 $ 63.672%0
James Barrow 2014-03-31 Reduce -86.22%0.5%$55.57 - $69.09 $ 63.672%960997
George Soros 2014-03-31 Add 64.82%0.22%$55.57 - $69.09 $ 63.672%850000
Vanguard Health Care Fund 2014-03-31 Reduce -7.7%0.15%$55.57 - $69.09 $ 63.672%10073000
John Hussman 2013-12-31 Reduce -49.41%0.43%$54.86 - $60.59 $ 63.679%150000
Vanguard Health Care Fund 2013-12-31 Reduce -12.46%0.29%$54.86 - $60.59 $ 63.679%10913200
John Keeley 2013-12-31 New Buy$54.86 - $60.59 $ 63.679%3682
George Soros 2013-09-30 New Buy0.29%$44.12 - $56.23 $ 63.6727%500000
John Hussman 2013-09-30 Add 46.42%0.28%$44.12 - $56.23 $ 63.6727%296500
Joel Greenblatt 2013-09-30 Sold Out 0.02%$44.12 - $56.23 $ 63.6727%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Walgreen Co

NEW SITE FEATURE: 10-Year Median Scans
GuruFocus has always delievered the most vast offering of equity research tools available on the market. Last year we introduced the All-In-One Guru Screener. It has been met with immensely positive feedback and has quickly become the go-to scanner for sophisticated investors. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.70
WAG's P/E(ttm) is ranked higher than
75% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.70 vs. WAG: 21.70 )
WAG' s 10-Year P/E(ttm) Range
Min: 10.2   Max: 32.02
Current: 21.7

10.2
32.02
P/B 2.84
WAG's P/B is ranked higher than
62% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. WAG: 2.84 )
WAG' s 10-Year P/B Range
Min: 1.6   Max: 5.58
Current: 2.84

1.6
5.58
P/S 0.81
WAG's P/S is ranked higher than
61% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. WAG: 0.81 )
WAG' s 10-Year P/S Range
Min: 0.36   Max: 1.2
Current: 0.81

0.36
1.2
PFCF 24.77
WAG's PFCF is ranked higher than
86% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 205.50 vs. WAG: 24.77 )
WAG' s 10-Year PFCF Range
Min: 9.86   Max: 368.77
Current: 24.77

9.86
368.77
EV-to-EBIT 14.90
WAG's EV-to-EBIT is ranked higher than
75% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.76 vs. WAG: 14.90 )
WAG' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 19.9
Current: 14.9

6.3
19.9
PEG 3.24
WAG's PEG is ranked higher than
84% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 30.50 vs. WAG: 3.24 )
WAG' s 10-Year PEG Range
Min: 0.69   Max: 4.13
Current: 3.24

0.69
4.13
Shiller P/E 24.45
WAG's Shiller P/E is ranked higher than
84% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 35.08 vs. WAG: 24.45 )
WAG' s 10-Year Shiller P/E Range
Min: 12.14   Max: 42.41
Current: 24.45

12.14
42.41
Current Ratio 1.42
WAG's Current Ratio is ranked higher than
79% of the 390 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.18 vs. WAG: 1.42 )
WAG' s 10-Year Current Ratio Range
Min: 1.23   Max: 1.93
Current: 1.42

1.23
1.93
Quick Ratio 0.65
WAG's Quick Ratio is ranked higher than
68% of the 390 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.70 vs. WAG: 0.65 )
WAG' s 10-Year Quick Ratio Range
Min: 0.27   Max: 0.82
Current: 0.65

0.27
0.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.00
WAG's Dividend Yield is ranked higher than
61% of the 445 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.82 vs. WAG: 2.00 )
WAG' s 10-Year Dividend Yield Range
Min: 0.44   Max: 3.11
Current: 2

0.44
3.11
Dividend Payout 0.43
WAG's Dividend Payout is ranked higher than
70% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. WAG: 0.43 )
WAG' s 10-Year Dividend Payout Range
Min: 0.1   Max: 0.7
Current: 0.43

0.1
0.7
Dividend growth (3y) 24.70
WAG's Dividend growth (3y) is ranked higher than
93% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.20 vs. WAG: 24.70 )
WAG' s 10-Year Dividend growth (3y) Range
Min: 3.7   Max: 26
Current: 24.7

3.7
26
Yield on cost (5-Year) 6.10
WAG's Yield on cost (5-Year) is ranked higher than
88% of the 450 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.99 vs. WAG: 6.10 )
WAG' s 10-Year Yield on cost (5-Year) Range
Min: 1.34   Max: 9.49
Current: 6.1

1.34
9.49
Share Buyback Rate 1.10
WAG's Share Buyback Rate is ranked higher than
87% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. WAG: 1.10 )
WAG' s 10-Year Share Buyback Rate Range
Min: 3.9   Max: -0.9
Current: 1.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.41
WAG's Price/Tangible Book is ranked higher than
67% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.39 vs. WAG: 3.41 )
WAG' s 10-Year Price/Tangible Book Range
Min: 1.94   Max: 10.32
Current: 3.41

1.94
10.32
Price/DCF (Projected) 1.41
WAG's Price/DCF (Projected) is ranked higher than
85% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.47 vs. WAG: 1.41 )
WAG' s 10-Year Price/DCF (Projected) Range
Min: 0.73   Max: 18.65
Current: 1.41

0.73
18.65
Price/Median PS Value 1.25
WAG's Price/Median PS Value is ranked higher than
68% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.14 vs. WAG: 1.25 )
WAG' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 3.19
Current: 1.25

0.57
3.19
Price/Peter Lynch Fair Value 3.51
WAG's Price/Peter Lynch Fair Value is ranked higher than
86% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. WAG: 3.51 )
WAG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 3.96
Current: 3.51

0.8
3.96
Price/Graham Number 1.78
WAG's Price/Graham Number is ranked higher than
75% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.26 vs. WAG: 1.78 )
WAG' s 10-Year Price/Graham Number Range
Min: 0.99   Max: 5.06
Current: 1.78

0.99
5.06
Earnings Yield (Greenblatt) 6.70
WAG's Earnings Yield (Greenblatt) is ranked higher than
72% of the 495 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.70 vs. WAG: 6.70 )
WAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5   Max: 15.9
Current: 6.7

5
15.9
Forward Rate of Return (Yacktman) 9.87
WAG's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 372 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.76 vs. WAG: 9.87 )
WAG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.9   Max: 17.8
Current: 9.87

9.9
17.8

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:WGN.Germany
Walgreen Company was incorporated in the state of Illinois in 1909 as a successor to a business founded in 1901. Its corporate strategy is to provide convenient access to healthcare services and consumer goods in America through its 7,930 community based drugstores, as well as through its specialty pharmacy, home infusion, worksite health center and retail clinic businesses. The Company's drugstores are engaged in the retail sale of prescription and non-prescription drugs and general merchandise. General merchandise includes, among other things, household items, personal care, convenience foods, beauty care, photofinishing, candy, and seasonal items. Walgreens offers customers the choice to have prescriptions filled at the drugstore counter, as well as through the mail, by telephone and via the Internet. Inventories are purchased from numerous domestic and foreign suppliers. The business is seasonal in nature, with Christmas generating a higher proportion of front-end sales and earnings than other periods. Both prescription and non-prescription drug sales are affected by the timing and severity of the cold/flu season. The Company generally finances its inventory and expansion needs with internally generated funds. It sells to numerous customers including managed care organizations. Walgreens competes with different retailers, including chain and independent drugstores, mail order prescription providers, grocery stores, convenient stores, mass merchants and dollar stores. Its retail drugstore, pharmacy benefit and health services businesses are subject to numerous federal, state and local regulations.
» More Articles for WAG

Headlines

Articles On GuruFocus.com
These 2 Companies Can Be Good Long-Term Picks Aug 22 2014 
Why You Should Invest In This Drugstore Retailer Aug 05 2014 
Is Walgreen Set For A Better 2014? Jul 28 2014 
Realty Income: Another BORING and Solid Quarter for the Monthly Dividend Company Jul 24 2014 
Looking beyond Walgreen’s Quarter Jul 21 2014 
Here's Why Rite Aid and Walgreens Are Still Solid Picks May 29 2014 
3 Stocks To Strike A Balance Between Dividend And Growth May 27 2014 
NEW SITE FEATURE: 10-Year Median Scans May 21 2014 
Rite Aid Corporation May Be a Buy: More Upside Expected May 20 2014 
Why I AM Buying American Realty Capital Properties Apr 28 2014 

More From Our Partners
Retail Sales Rise: 2 Pharmacy Stocks in Focus - Analyst Blog Sep 16 2014 - ZACKS

More From Other Websites
WALGREEN CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 16 2014
8:12 am Walgreens Boots Alliance files Form S-4 registration statement and preliminary proxy... Sep 16 2014
Walgreens Boots Alliance Files Form S-4 Registration Statement and Preliminary Proxy... Sep 16 2014
Labor pension adviser CtW seeks details from Walgreen Sep 12 2014
Top 5 Retailers Partnering With Apple On Its E-Wallet Sep 11 2014
With new CEO, Target ready to move forward Sep 10 2014
Power Struggle at Walgreen as Biggest Shareholder Rises Sep 10 2014
Top U.S. Senate Democrats unveil earnings stripping plan Sep 10 2014
Economic News Today: S&P Warns On Tax Inversions Sep 10 2014
[video] Sen. Schumer's inversion compromise Sep 10 2014
[video] Apple CEO Tim Cook Unveils 'Apple Watch,' iPhone 6 and 'Apple Pay' Sep 09 2014
First look at Apple's iPhones, mobile pay, Apple Watch Sep 09 2014
Your first trade for Wednesday Sep 09 2014
Apple hopes to jump-start mobile payments with Apple Pay Sep 09 2014
Why Apple Pay and PayPal Could Be 'Frenemies' Sep 09 2014
Walgreens and United Nations Foundation Launch “Get a Shot. Give a Shot” Campaign, Kicking Off... Sep 09 2014
[video] FMHR Final Trade: All about Apple Sep 09 2014
Why Walgreen (WAG) Stock Is Gaining Today Sep 09 2014
[video] Mossberg: Fruition of Tim Cook's Apple Sep 09 2014
Walgreen Pressured to Up Buyback as Activist Wins Seats Sep 09 2014
[$$] Activist Investor Scores a Win at Walgreen Sep 08 2014
Jana Partners wins Walgreen board seats Sep 08 2014
[video] Main Street Investors Dial Back Exposure a Touch in August Sep 08 2014
Jim Cramer's Mad Dash: Walgreens to Benefit From Increased Number of Activist Investors Sep 08 2014
Walgreen adds activist hedge fund founder to board Sep 08 2014
Jana Partners wins Walgreen board seats Sep 08 2014
Key Walgreen revenue metric rises 3.7 pct Sep 04 2014
Walgreen stores go offline due to technical glitch Aug 22 2014
Walgreen CFO's departure due to $1 bln forecasting error - WSJ Aug 20 2014
Ahead of the Bell: Walgreen shares stage rally Aug 07 2014
Walgreens set to acquire Boots in 9 bln pounds deal Aug 07 2014
Walgreen to keep U.S. tax domicile after buying Alliance Boots Aug 06 2014
Walgreen to keep U.S. tax domicile after buying Alliance Boots Aug 06 2014
Walgreens to buy all of Alliance Boots, stay in US Aug 06 2014
Share buy-back puts Walgreen on downgrade watch Aug 06 2014
Walgreen turns down inversion to cut tax bill Aug 06 2014
Walgreen to keep U.S. tax domicile after buying Alliance Boots Aug 06 2014
Walgreen to keep U.S. tax domicile after buying Alliance Boots Aug 06 2014
Walgreens to take full control of Alliance Boots Aug 06 2014
Walgreens Confirms Full Takeover of Boots Aug 06 2014
Boots boss sits on $12bn fortune from Walgreens deal Aug 06 2014
Boots boss sits on $10bn fortune from Walgreens deal Aug 06 2014
Boots deal nets 'king of pharmacies' a £6bn stake in Walgreens Aug 06 2014
UPDATE 2-Walgreen to keep U.S. tax domicile as buys Alliance Boots Aug 06 2014
Walgreens to buy all of Alliance Boots, stay in US Aug 06 2014
Walgreens says taking full control of Alliance Boots Aug 06 2014
Walgreen won't shift tax domicile abroad as buys Alliance Boots Aug 06 2014
Walgreen retreats from plan to move tax domicile abroad Aug 06 2014
Walgreens Shuns Inversion In £5bn Boots Deal Aug 06 2014
Walgreens to take full control of Alliance Boots Aug 05 2014
Walgreens says taking full control of Alliance Boots Aug 05 2014
Walgreens set to buy remaining stake in Alliance Boots - UPDATE Aug 05 2014
Walgreen drops on report it will keep US tax base Aug 05 2014
Walgreen retreats from plan to move tax domicile abroad Aug 05 2014
Key Walgreen revenue metric rises 5.2 pct in July Aug 05 2014
Walgreen CFO leaves, replaced with Kraft exec Aug 04 2014
Walgreens, diabetic employee reach $180,000 deal Jul 03 2014
Pharmacy sales boost major drugstores in June Jul 03 2014
Walgreens, diabetic employee reach $180K deal Jul 03 2014
Walgreen 3Q profit jumps but misses expectations Jun 24 2014
Missouri will audit Walgreen stores for 3 years Jun 04 2014
Key Walgreen revenue metric rises 4.4 pct in May Jun 04 2014
Alliance Boots makes more synergies with Walgreens May 15 2014
Cardinal Health fiscal 3Q profit falls about 9 pct May 01 2014
Pharmacy sales deliver March boost to drugstores Apr 03 2014
Walt Disney and Carnival are big market movers Mar 25 2014
Walgreen Co. Reports Fiscal 2014 Second Quarter Results Mar 25 2014
Walgreens Second Quarter 2014 Earnings Release, Conference Call Scheduled for March 25 Mar 24 2014
Walgreens and MyMedicalRecords Reach Settlement Agreement Mar 06 2014
Walgreens Extends Through April 15 Offer to Provide Up to 30-Day Prescription Supply at No Upfront... Feb 10 2014
Walgreens January Sales Increase 3.7 Percent Feb 05 2014
Walgreens to Provide Blood Pressure Testing at No Cost Throughout February in Support of American... Feb 04 2014
Walgreens Brings Big Data Analytics to Healthcare Clinics Through Expanded Relationship with... Jan 30 2014
Walgreens Reaches Goal to Donate the Value of Three Million Life-Saving Vaccines in Developing... Jan 15 2014
Centura Health and Walgreens Announce Clinical Collaboration Agreement Jan 14 2014
Walgreens Declares Regular Quarterly Dividend Jan 09 2014
Walgreens Outlines Growth Opportunities and Strategy at 2014 Annual Shareholders Meeting Jan 08 2014
Walgreens December Sales Increase 7.2 Percent Jan 06 2014
Walgreens Earns Top Marks in 2014 Corporate Equality Index Dec 30 2013
Walgreen Co. Reports Fiscal 2014 First Quarter Results Dec 20 2013
Walgreens Convenient Hours and Locations Help Make Last-Minute Shopping Easy Dec 17 2013
Walgreens First Quarter 2014 Earnings Release, Conference Call Scheduled for Dec. 20 Dec 13 2013
Walgreens Debuts Nation’s First Net Zero Energy Retail Store in Evanston, Ill. Nov 21 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK